BID | 117.00 | ASK | 118.00 | ||
Open | 113.24 | Previous Close | 113.99 | ||
Pre-Market | 117.50 | After-Market | - | ||
0.37 0.32% | - - |
Target Price | 258.71 | Analyst Rating | Hold 2.69 | |
Potential % | 120.87 | Finscreener Ranking | ★+ 44.07 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | + 36.58 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★+ 43.55 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 18.81 | Earnings Rating | Strong Sell | |
Market Cap | 18.60B | Earnings Date | 9th Nov 2023 | |
Alpha | -0.02 | Standard Deviation | 0.11 | |
Beta | 1.09 |
Today's Price Range 113.00117.60 | 52W Range 89.00238.55 | 5 Year PE Ratio Range 29.20124.90 |
Summary:
Neutral
Technical Indicators: | Buy |
Moving Averages: | Neutral |
Performance | |||
---|---|---|---|
1 Week | 6.69% | ||
1 Month | 5.81% | ||
3 Months | -26.04% | ||
6 Months | -42.22% | ||
1 Year | -45.33% | ||
3 Years | -65.82% | ||
5 Years | -63.56% | ||
10 Years | 18.02% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 10.89 | |||
ROE last 12 Months | -52.89 | |||
ROA (5Y Avg) | 3.95 | |||
ROA last 12 Months | -34.58 | |||
ROC (5Y Avg) | 12.71 | |||
ROC last 12 Months | -36.90 | |||
Return on invested Capital Q | -34.16 | |||
Return on invested Capital Y | 0.91 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 5.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-7.60 | ||||
4.72 | ||||
9.31 | ||||
60.10 | ||||
-145.70 | ||||
3.36 | ||||
200.98 | ||||
42.79 | ||||
33.28B | ||||
Forward PE | 103.57 | |||
PEG | -0.34 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.60 | ||||
0.90 | ||||
0.16 | ||||
0.37 | ||||
-135.10 | ||||
Leverage Ratio | 1.50 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
66.30 | ||||
-86.20 | ||||
-78.20 | ||||
27.00 | ||||
-88.38 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.50B | ||||
22.26 | ||||
8.95 | ||||
10.93 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | 0.13 | 0.33 | 153.85 |
Q02 2023 | 0.02 | 0.32 | 1.50K |
Q01 2023 | 0.02 | 0.08 | 300.00 |
Q04 2022 | 0.19 | 0.14 | -26.32 |
Q03 2022 | 0.29 | 0.34 | 17.24 |
Q02 2022 | 0.63 | 0.57 | -9.52 |
Q01 2022 | 0.87 | 1.07 | 22.99 |
Q04 2021 | 0.50 | 0.75 | 50.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2023 QR | -0.01 | -103.45 | Negative |
12/2023 FY | 0.68 | -18.07 | Negative |
3/2024 QR | 0.12 | -67.57 | Negative |
12/2024 FY | 1.06 | -56.56 | Negative |
Next Report Date | - |
Estimated EPS Next Report | 0.13 |
Estimates Count | 8 |
EPS Growth Next 5 Years % | 22.20 |
Volume Overview | |
---|---|
Volume | 2.11M |
Shares Outstanding | 158.80K |
Shares Float | 158.44M |
Trades Count | 44.29K |
Dollar Volume | 246.36M |
Avg. Volume | 2.98M |
Avg. Weekly Volume | 2.95M |
Avg. Monthly Volume | 3.64M |
Avg. Quarterly Volume | 2.34M |
Illumina Inc. (NASDAQ: ILMN) stock closed at 117.13 per share at the end of the most recent trading day (a 2.75% change compared to the prior day closing price) with a volume of 2.11M shares and market capitalization of 18.60B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 7850 people. Illumina Inc. CEO is Francis A. DeSouza.
The one-year performance of Illumina Inc. stock is -45.33%, while year-to-date (YTD) performance is -42.07%. ILMN stock has a five-year performance of -63.56%. Its 52-week range is between 89 and 238.55, which gives ILMN stock a 52-week price range ratio of 18.81%
Illumina Inc. currently has a PE ratio of -7.60, a price-to-book (PB) ratio of 4.72, a price-to-sale (PS) ratio of 9.31, a price to cashflow ratio of 60.10, a PEG ratio of -0.34, a ROA of -34.58%, a ROC of -36.90% and a ROE of -52.89%. The company’s profit margin is -88.38%, its EBITDA margin is -78.20%, and its revenue ttm is $3.50 Billion , which makes it $22.26 revenue per share.
Of the last four earnings reports from Illumina Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.13 for the next earnings report. Illumina Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Illumina Inc. is Hold (2.69), with a target price of $258.71, which is +120.87% compared to the current price. The earnings rating for Illumina Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Illumina Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Illumina Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.30, ATR14 : 5.28, CCI20 : 135.05, Chaikin Money Flow : 0.22, MACD : -0.55, Money Flow Index : 66.37, ROC : 20.00, RSI : 59.93, STOCH (14,3) : 97.37, STOCH RSI : 1.00, UO : 67.93, Williams %R : -2.63), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Illumina Inc. in the last 12-months were: Aimee L. Hoyt (Option Excercise at a value of $0), Aimee L. Hoyt (Sold 4 788 shares of value $958 789 ), Alexander Aravanis (Option Excercise at a value of $0), Alexander Aravanis (Sold 5 398 shares of value $1 088 982 ), Charles E. Dadswell (Option Excercise at a value of $0), Dadswell Charles (Option Excercise at a value of $0), Francis A. DeSouza (Option Excercise at a value of $0), Hoyt Aimee (Option Excercise at a value of $0), Hoyt Aimee (Sold 5 103 shares of value $994 314 ), Joydeep Goswami (Option Excercise at a value of $0), Kathryne Gambrell Reeves (Option Excercise at a value of $0), Kevin Carl Pegels (Option Excercise at a value of $0), Phillip G. Febbo (Option Excercise at a value of $0), Reeves Kathryne (Option Excercise at a value of $0), Susan H. Tousi (Option Excercise at a value of $0), Susan H. Tousi (Sold 1 000 shares of value $208 075 ), Tousi Susan (Option Excercise at a value of $0), Tousi Susan (Sold 7 000 shares of value $1 434 570 ), TOUSI SUSAN H (Sold 500 shares of value $100 000 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Hold | Moderate Buy | Moderate Buy |
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
CEO: Francis A. DeSouza
Telephone: +1 858 202-4500
Address: 200 Illumina Way, San Diego 92122, CA, US
Number of employees: 7 850
Mon, 16 Oct 2023 10:02 GMT Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), UnitedHealth (UNH) and BeiGene (BGNE)
- TipRanks. All rights reserved.Mon, 09 Oct 2023 18:51 GMT EU regulators to order Illumina to divest cancer test firm Grail, FT reports
- TipRanks. All rights reserved.Fri, 01 Sep 2023 13:55 GMT Early notable gainers among liquid option names on September 1st
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.